Clinical trial
Aripiprazole for the Treatment of Refractory Anxiety
NCT00438386 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00438386 |
|---|---|
| Title | Aripiprazole for the Treatment of Refractory Anxiety |
| Official title | Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Generalized Anxiety Disorder, Panic Disorder |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Start date | Apr 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Feb 22, 2007 |
| Last update posted | Aug 10, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: